PSA after prostatectomy: what should it be, and what if it rises?

What should PSA be after the prostate is removed?

Undetectable: after a radical prostatectomy, PSA should fall below the level your laboratory can measure. PSA is made by prostate cells, benign and cancerous alike. Once the whole gland has been removed, nothing should be left to produce it.

The fall takes time. In an early study published in the New England Journal of Medicine (Stamey and colleagues, 1987), PSA routinely fell to undetectable levels after radical prostatectomy, with a half-life of 2.2 days. Each half-life removes half of what is still in the blood, so a man with a high PSA before surgery needs more of them. The study is old and used an early version of the test, but the principle still guides the timing.

At this practice the first PSA is measured 4 to 6 weeks after surgery. The European Association of Urology (EAU) guideline expects PSA to be undetectable two months after the operation. A test done in the first days can still show PSA left over from before surgery and cause worry for no reason.

How often should PSA be tested, and for how long?

Often in the first years, then once a year, and for much longer than most men expect. At this practice, PSA is usually checked every 3 months in the first year. The EAU guideline recommends a PSA test and a short disease-specific history every six months for three years, and then annually. It adds that the evidence for any specific interval is low, so your surgeon may adapt the schedule to your pathology report.

Limits: the intervals rest on expert agreement more than on trials. Tumour or patient characteristics may justify closer or longer follow-up.

Why so long? According to the same guideline, approximately 50% of recurrences are to be expected beyond three years, and a rising PSA may appear up to 20 years after treatment. A PSA rise almost always comes before any other sign of recurrence, which is why the blood test matters more than examinations. Scans have no place in routine follow-up as long as PSA is not rising.

What do "undetectable" and "ultrasensitive PSA" mean?

"Undetectable" means below the lowest value your laboratory's test can report, and that limit is not the same for every test. A standard test often reports the result as "less than 0.1 ng/mL". An ultrasensitive test can report values in hundredths of a nanogram, such as 0.01 ng/mL.

More decimals are not always more helpful. The EAU guideline describes ultrasensitive tests as still controversial for routine follow-up after prostatectomy. They can reassure: in data cited by the guideline, men whose lowest PSA was below 0.01 ng/mL had a high (96%) likelihood of remaining relapse-free within two years. A value above 0.01 ng/mL, read together with the tumour grade and the surgical margins, may help to predict a later rise and to set the testing interval.

What a very low reading cannot do is diagnose recurrence. At this level, a shift in the second decimal place can come from the test itself or from a change of laboratory. The guideline counts only a confirmed rising PSA as a sign of recurrence. One low result that does not climb on the next tests is not a relapse.

What counts as biochemical recurrence?

The most widely used definition is a PSA of 0.2 ng/mL or more, confirmed by a second measurement above 0.2 ng/mL. "Biochemical" means that the blood test is the only sign: there are no symptoms, and scans are often normal.

This definition comes from an American Urological Association panel (Cookson and colleagues, 2007), which found 53 different definitions in 145 published articles on prostatectomy and proposed one standard. The panel stressed that it is a standard for reporting results, not a level at which treatment must begin.

The current EAU guideline is more cautious. It describes recurrence as a rising PSA after prostatectomy and states that no definitive threshold can be given. Its evidence summary notes that the threshold that most closely predicts later metastases is a PSA above 0.4 ng/mL, and that a detectable PSA has to be distinguished from a clinically meaningful relapse. The randomised trials acted earlier: RADICALS-RT started radiotherapy at 0.1 ng/mL or more or after three consecutive rises, and RAVES at 0.20 ng/mL or more.

Limits: these values are conventions drawn from guidelines and trials, not sharp borders. The trend over several tests in the same laboratory matters more than a single number.

What does it mean if PSA never becomes undetectable?

A PSA that is still 0.1 ng/mL or higher at the first test is called persistent PSA, and it deserves prompt attention. It suggests that PSA-producing cells remain somewhere: in the area where the prostate was, in lymph nodes, or elsewhere. Occasionally the source is benign prostate tissue left at the edge of the operation.

In a study of 11,604 men operated on at one high-volume centre (Preisser and colleagues, 2019), 8.8% had a PSA of 0.1 ng/mL or more at 6 weeks. Fifteen years after surgery, metastasis-free survival was 53.0% in these men, compared with 93.2% in men whose PSA was undetectable. Cancer-specific survival was 75.5% versus 96.2%. Salvage radiotherapy was associated with better survival in a matched comparison.

Limits: this was a retrospective, single-centre analysis, and details of later PSA values and hormone treatment were incomplete. The usual steps are to repeat the test, to read it alongside the pathology report, and to discuss imaging and early radiotherapy.

Does a rising PSA mean the cancer will spread?

Not necessarily. For many men a rising PSA never becomes a threat to life, and when spread does occur it usually takes years.

The classic description is a large surgical series published in JAMA (Pound and colleagues, 1999). Of 1,997 men operated on by a single surgeon, 315 (15%) developed a PSA rise. Among the 304 who received no early hormone therapy, 103 (34%) developed metastases during the study, and the median time from the PSA rise to metastases was 8 years. Limits: the operations were done between 1982 and 1997, at one institution, with the imaging of that era.

A systematic review of 77 studies for the EAU (Van den Broeck and colleagues, 2019) found that recurrence was linked to worse survival mainly in men with a short PSA doubling time and a high final Gleason score. This is the basis of the EAU risk groups:

• High-risk recurrence: a PSA doubling time of 1 year or less, or a pathological grade group of 4 to 5.
• Low-risk recurrence: neither of these.

In a population-based study of 12,010 men who had a prostatectomy in Stockholm (Falagario and colleagues, 2025), the 10-year incidence of high-risk recurrence by the EAU definition was 10%, and up to 50% of men with a recurrence never progressed to the high-risk form. The doubling time is calculated from several dated results, which is one reason to keep a careful record.

What does the pathology report add?

It tells you, before the first PSA test, how closely the PSA needs watching. Four findings matter most. The randomised trials of radiotherapy after surgery selected men by margins, tumour extent and grade.

• Surgical margins. A positive margin means tumour cells reach the cut edge. In a retrospective study of 1,039 robotic prostatectomies at one European institution (Hagman and colleagues, 2025), 21.8% had a positive margin. An extensive positive margin was linked to a higher risk of recurrence in every risk group. A focal one was linked to additional treatment only in men with high-risk tumours.
• Extracapsular extension and seminal vesicle invasion (stage pT3a and pT3b). Both mean the tumour had grown beyond the gland.
• Lymph nodes. Tumour in the removed nodes makes a persistent or rising PSA more likely and changes the plan.
• Grade. The final Gleason score, or grade group, enters the EAU risk groups directly.

None of these findings is a recurrence in itself. They decide how strictly the schedule is followed and how early a rise is acted on.

What happens next if PSA rises?

The result is confirmed, the risk is estimated, and then you and your doctors choose between continued monitoring and radiotherapy.

Imaging. The EAU guideline advises imaging at recurrence only if the result will change the treatment plan. A PSMA PET scan can find the source at low PSA values, but not always. In a meta-analysis of 37 articles and 4,790 patients (Perera and colleagues, 2020), the scan was positive in 33% of men with a PSA of 0 to 0.19 ng/mL, 45% at 0.2 to 0.49, 59% at 0.5 to 0.99, 75% at 1 to 1.99 and 95% at 2 ng/mL or more. A negative scan at a low PSA is therefore common and does not exclude recurrence.

Radiotherapy. Salvage radiotherapy treats the area where the prostate was. The alternative strategy, adjuvant radiotherapy, treats every man with risk features soon after surgery without waiting for the PSA. Three randomised trials compared the two.

Limits: the trials reported PSA-based outcomes after about five years; data on metastases and survival are still maturing. Most participants (77.6% in the meta-analysis) had a Gleason score of 7, so the results are less certain for men with several adverse findings. RAVES did not formally meet its non-inferiority criteria.

Hormone therapy. In RADICALS-HD, adding 6 months of hormone therapy to radiotherapy after surgery did not improve metastasis-free survival at 10 years (80.4% with it, 79.2% without). Whether a longer course is worthwhile in higher-risk situations is decided individually, usually with a radiation oncologist. For low-risk recurrence, continued monitoring may be an option.

Radiotherapy after surgery can affect urinary control and erections. These effects are covered in the article on the side effects of prostate removal.

How should you organise PSA testing at home?

Use the same laboratory and the same test every time, keep every result with its date, and send each one to your surgeon.

• One laboratory, one test. Different tests can give slightly different values for the same blood sample. Ask the laboratory which test it uses and what its lowest reportable value is.
• A dated record. Write down the date, the value, the unit (ng/mL) and the laboratory. The doubling time can only be calculated from dated results.
• Send every result, including the normal ones. An unbroken record is more useful than a single alarming value.
• Do not skip a test because you feel well. A rising PSA causes no symptoms.
• Repeat before you worry. An unexpected value is first repeated in the same laboratory.

If you travel for surgery: your follow-up will be done by your own doctor at home. Take the pathology report, the operation note and the medical letter with you, and arrange the first PSA 4 to 6 weeks after surgery before you leave. Practical planning is covered in the guide to prostate surgery in Turkey, and treatment itself on the prostate cancer page.

Which questions should you ask your surgeon?

Ask what your own pathology report means for your follow-up.

• Were the surgical margins clear? If not, was the positive margin focal or extensive?
• What were the final stage and grade group, and were the lymph nodes clear?
• How often should I test in the first year, and when can the interval lengthen?
• Should my laboratory use a standard or an ultrasensitive test?
• At which PSA value, or after how many rises, do you want to hear from me at once?
• If my PSA rises, who will calculate the doubling time and discuss imaging and radiotherapy with me?
• Whom should my doctor at home contact with questions?

This article gives general information and does not replace an assessment of your own scans and results. Treatment is decided individually.